- Home
- DMAC vs PVBC Comparison
DMAC vs PVBC Comparison
Compare DMAC & PVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- PVBC
- Stock Information
- Founded
- DMAC 2000
- PVBC 1913
- Country
- DMAC United States
- PVBC United States
- Employees
- DMAC N/A
- PVBC N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- PVBC Major Banks
- Sector
- DMAC Health Care
- PVBC Finance
- Exchange
- DMAC Nasdaq
- PVBC Nasdaq
- Market Cap
- DMAC 178.0M
- PVBC 202.6M
- IPO Year
- DMAC N/A
- PVBC 2015
- Fundamental
- Price
- DMAC $3.63
- PVBC $11.84
- Analyst Decision
- DMAC Strong Buy
- PVBC Hold
- Analyst Count
- DMAC 2
- PVBC 1
- Target Price
- DMAC $8.00
- PVBC $12.50
- AVG Volume (30 Days)
- DMAC 110.0K
- PVBC 302.4K
- Earning Date
- DMAC 08-06-2025
- PVBC 07-28-2025
- Dividend Yield
- DMAC N/A
- PVBC N/A
- EPS Growth
- DMAC N/A
- PVBC N/A
- EPS
- DMAC N/A
- PVBC 0.26
- Revenue
- DMAC N/A
- PVBC $50,244,000.00
- Revenue This Year
- DMAC N/A
- PVBC $9.73
- Revenue Next Year
- DMAC N/A
- PVBC $4.87
- P/E Ratio
- DMAC N/A
- PVBC $45.18
- Revenue Growth
- DMAC N/A
- PVBC N/A
- 52 Week Low
- DMAC $2.14
- PVBC $9.48
- 52 Week High
- DMAC $6.82
- PVBC $12.96
- Technical
- Relative Strength Index (RSI)
- DMAC 46.56
- PVBC 64.66
- Support Level
- DMAC $4.02
- PVBC $11.66
- Resistance Level
- DMAC $4.17
- PVBC $11.91
- Average True Range (ATR)
- DMAC 0.25
- PVBC 0.18
- MACD
- DMAC -0.04
- PVBC 0.02
- Stochastic Oscillator
- DMAC 37.89
- PVBC 70.11
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.